5-YEAR RELATIVE SURVIVAL RATE BETWEEN SEMINOMA AND NON-SEMINOMA TESTICULAR CANCER IN SINGLE CENTER

Ben Julian Mantiri, G. P. Siregar, Syah Mirsya
{"title":"5-YEAR RELATIVE SURVIVAL RATE BETWEEN SEMINOMA AND NON-SEMINOMA TESTICULAR CANCER IN SINGLE CENTER","authors":"Ben Julian Mantiri, G. P. Siregar, Syah Mirsya","doi":"10.32421/juri.v30i3.829","DOIUrl":null,"url":null,"abstract":"ABSTRACT \nObjective: This study was conducted to provide data about the survival rate of testicular cancer patients with different histology in the year 2013 – 2017 in Adam Malik General Hospital and to compare these estimates with other studies conducted in another center. Material & Methods: Medical records of testicular cancer patients from 2013 to 2017 in Adam Malik General Hospital were collected. We measured 5-year relative survival between the histology group of seminoma and non-seminoma estimated using Kaplan-Meier survival analysis. Also, using Kaplan-Meier for survival analysis estimated, 5-year relative survival between metastatic and non-metastatic was estimated. Results: 63 male patients (mean age 27.5 ± 17.6 years old) were included in this study. The distribution of histology were non-seminoma (53.9%), seminoma (39.9%), non-Hodgkin lymphoma (4.7%), and gonadoblastoma (1.5%). The 5-year relative survival rate was 82.5% for the seminoma group and 80.9 % for the non-seminoma group. The 5-year survival rate in the seminoma group with metastatic was 77.8% and in the non-metastatic group was 87.3 %. The 5-year survival rate in the non-seminoma group with metastatic was 74.6 % and in the non-metastatic group was 88.9 %. Conclusion: 5-year relative survival was better for the seminoma group than the non-seminoma group. Moreover, non-metastasis seminoma was found to have a better outcome than the metastatic group. Despite that, in the non-metastatic group, it is found that non-seminoma testicular cancer has a better survival rate than seminoma testicular cancer. \nKeywords: 5-year relative survival rate, seminoma, non-seminoma, testicular cancer.","PeriodicalId":13565,"journal":{"name":"Indonesian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32421/juri.v30i3.829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Objective: This study was conducted to provide data about the survival rate of testicular cancer patients with different histology in the year 2013 – 2017 in Adam Malik General Hospital and to compare these estimates with other studies conducted in another center. Material & Methods: Medical records of testicular cancer patients from 2013 to 2017 in Adam Malik General Hospital were collected. We measured 5-year relative survival between the histology group of seminoma and non-seminoma estimated using Kaplan-Meier survival analysis. Also, using Kaplan-Meier for survival analysis estimated, 5-year relative survival between metastatic and non-metastatic was estimated. Results: 63 male patients (mean age 27.5 ± 17.6 years old) were included in this study. The distribution of histology were non-seminoma (53.9%), seminoma (39.9%), non-Hodgkin lymphoma (4.7%), and gonadoblastoma (1.5%). The 5-year relative survival rate was 82.5% for the seminoma group and 80.9 % for the non-seminoma group. The 5-year survival rate in the seminoma group with metastatic was 77.8% and in the non-metastatic group was 87.3 %. The 5-year survival rate in the non-seminoma group with metastatic was 74.6 % and in the non-metastatic group was 88.9 %. Conclusion: 5-year relative survival was better for the seminoma group than the non-seminoma group. Moreover, non-metastasis seminoma was found to have a better outcome than the metastatic group. Despite that, in the non-metastatic group, it is found that non-seminoma testicular cancer has a better survival rate than seminoma testicular cancer. Keywords: 5-year relative survival rate, seminoma, non-seminoma, testicular cancer.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单中心精原细胞瘤与非精原细胞瘤睾丸癌的5年相对生存率
【摘要】目的:本研究旨在提供2013 - 2017年亚当马利克综合医院不同组织学睾丸癌患者的生存率数据,并与其他中心的研究结果进行比较。材料与方法:收集2013 - 2017年亚当马利克综合医院睾丸癌患者的医疗记录。我们测量了精原细胞瘤和非精原细胞瘤组织学组的5年相对生存率,使用Kaplan-Meier生存分析估计。此外,使用Kaplan-Meier进行生存分析估计,估计转移性和非转移性之间的5年相对生存率。结果:共纳入63例男性患者,平均年龄27.5±17.6岁。组织学分布为非精原细胞瘤(53.9%)、精原细胞瘤(39.9%)、非霍奇金淋巴瘤(4.7%)和性腺母细胞瘤(1.5%)。精原细胞瘤组和非精原细胞瘤组的5年相对生存率分别为82.5%和80.9%。转移性精原细胞瘤组5年生存率为77.8%,非转移性精原细胞瘤组5年生存率为87.3%。非精原细胞瘤转移组5年生存率为74.6%,非转移组为88.9%。结论:精原细胞瘤组5年相对生存率高于非精原细胞瘤组。此外,非转移性精原细胞瘤的预后优于转移性精原细胞瘤。尽管如此,在非转移组中,发现非精原细胞瘤睾丸癌的生存率高于精原细胞瘤睾丸癌。关键词:5年相对生存率,精原细胞瘤,非精原细胞瘤,睾丸癌
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PRELIMINARY RESULTS OF DELAYED PRIMARY BLADDER EXSTROPHY RECONSTRUCTION IN FEMALE PATIENT: A CASE REPORT THE EFFECT OF TAMSULOSIN 0.4 MG ADMINISTRATION TOWARDS ALTERATION OF PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN BENIGN PROSTATIC HYPERPLASIA (BPH) PATIENTS IN PADANG CITY THE INDONESIAN LINGUISTIC VALIDATION OF THE URINARY STENT RELATED HEALTH QUESTIONNAIRE SINGLE SESSION BILATERAL PERCUTANEOUS NEPHROLITHOTOMY (PCNL) IN HORSESHOE KIDNEY PATIENT WITH BILATERAL STAGHORN STONES: A CASE REPORT PROFILE OF NEPHROLITHIASIS PATIENTS TREATED WITH MINI-PERCUTANEOUS NEPHROLITHOTOMY (MINI-PCNL): A SINGLE CENTER EXPERIENCE IN JAMBI, INDONESIA
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1